Lanxess

Lanxess reports an adjusted earnings increase of about 11% to €139m in the third quarter and revenue growth of almost 10% to around €1.47bn. Free cash flow swung from -€14m to +€48m, but a net loss of €70m remained due to high write-downs. Management guides adjusted EBITDA for 2026 at the upper end of the €450–500m range; the Q4 outlook is above pessimistic market expectations. In addition to the results, short-covering and a technical move above the 50-day line likely helped drive the sharp share-price jump. » Mere på deraktionaer.de

Chemical stocks gained ahead of the EU summit in Brussels as measures to protect against Chinese imports of chemical products could be discussed. Lanxess recorded the strongest gains with an increase of four percent; BASF and Evonik also rose. Analysts point to parallels with the agreement on hybrid vehicles and to previous price increases for affected companies during EU investigations. Despite the price gains, the authors currently advise against buying Lanxess; stop-loss levels of €39.00 for BASF and €16.00 for Evonik are mentioned. » Mere på deraktionaer.de

Rating agency Scope has lowered LANXESS's issuer rating from BBB to BBB- and upgraded the outlook from negative to stable. The downgrade is justified by growing structural problems, overcapacity in the sector, stronger competition from Asian suppliers and an now structural weakness in demand. In XETRA trading the share is reacting with slight losses and is trading at around €12.33. » Mere på finanzen.net

Scope cut LANXESS’s issuer rating from BBB to BBB- and raised the outlook from negative to stable. The move is justified by growing structural challenges, sector overcapacity and increased competition from Asian rivals; demand weakness is becoming increasingly structural. In Tradegate trading, LANXESS shares gained 0.64 percent after hours to €12.63. » Mere på finanzen.net

LANXESS shares fell more than 5% at times and hit their lowest level since March, weighed down by rising energy costs. The September decline in the European chemical sector continued, with BASF and Evonik also dropping sharply. Analysts turned more cautious: JPMorgan cut its price target for LANXESS, Morgan Stanley moved Evonik to equal-weight, while hopes of a temporary boom from supply outages are fading. » Mere på finanzen.net